ath-1017
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 9, 2017 (NCT03298672)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorACTIVATOR
MET activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05511558 | Phase 1 | Jul 13, 2022 | Alturas Analytics, Inc., Athira Pharma, LabCorp |
| NCT04831281 | Phase 2 | Oct 31, 2021 | Athira Pharma |
| NCT04886063 | Phase 2 | Jun 30, 2021 | Athira Pharma |
| NCT04491006 | Phase 2 | Nov 23, 2020 | Athira Pharma, National Institute on Aging (NIA) |
| NCT04488419 | Phase 2 | Sep 28, 2020 | Athira Pharma |
| NCT03298672 | Phase 1 | Oct 9, 2017 | Alzheimer’s Drug Discovery Foundation, Athira Pharma, Biotrial |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Athira Pharma | For profit | 6 | 6 | 2 | 2017 |
| Alturas Analytics, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Alzheimer’s Drug Discovery Foundation | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Biotrial | For profit | 1 | 0 | 1 | 2017 |
| LabCorp | For profit | 1 | 0 | 1 | 2022 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1